Aerodynamic characteristics of dry powder inhaler (DPI) single-dose combination of budesonide with formoterol in vitro study validation

A.L. Fernandes, M.A. Lima, L.F.F. Pereira (Sao Paulo, Rio de Janeiro, Belo Horizonte, Brazil)

Source: Annual Congress 2012 - The best of pharmacology treatments of airway diseases: new devices and drugs
Session: The best of pharmacology treatments of airway diseases: new devices and drugs
Session type: Thematic Poster Session
Number: 2141
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
A.L. Fernandes, M.A. Lima, L.F.F. Pereira (Sao Paulo, Rio de Janeiro, Belo Horizonte, Brazil). Aerodynamic characteristics of dry powder inhaler (DPI) single-dose combination of budesonide with formoterol in vitro study validation. Eur Respir J 2012; 40: Suppl. 56, 2141

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Comparability of formoterol dry powder (DPI) and metered dose inhalers (MDI) in asthma
Source: Eur Respir J 2005; 26: Suppl. 49, 50s
Year: 2005

Once-daily budesonide: clinical equivalence of two dry powder inhalers (DPIs)
Source: Eur Respir J 2005; 26: Suppl. 49, 339s
Year: 2005

Bronchodilator effect of formoterol delivered by two different dry powder inhalers (DPI)
Source: Eur Respir J 2004; 24: Suppl. 48, 310s
Year: 2004

Comparison of a dry powder inhaler (DPI) to a pressurized metered-dose inhaler (pMDI) formulation of extra fine beclomethasone dipropionate/formoterol fumarate/glycopyrronium bromide (BDP/FF/GB) in patients with COPD: The TRI-D study.
Source: Virtual Congress 2020 – COPD : inhaled corticosteroids, bronchodilators and eosinophils
Year: 2020


Comparison of a formoterol multiple dose dry powder inhaler (MDPI) with a formoterol single dose dry powder inhaler (SDPI) in patients with moderate to severe asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 260s
Year: 2004

Efficacy of formoterol and beclomethasone dry powder capsules in asthmatic patients sub-optimally controlled with the fixed combination formoterol-budesonide (ALLIANCE study)
Source: Eur Respir J 2004; 24: Suppl. 48, 261s
Year: 2004

Patients’ ability to use a novel fluticasone propionate/formoterol breath-triggered inhaler (BTI) vs. budesonide/formoterol dry powder inhaler (DPI)
Source: International Congress 2018 – Innovative therapies in asthma and COPD
Year: 2018



Beclometasone/formoterol administered via extrafine dry powder inhaler in controlled asthmatic patients: Comparison with pMDI and beclometasone monotherapy
Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma
Year: 2012


Efficacy of formoterol 12μg dry powder capsules in 6,155 asthmatic patients poorly controlled with salmeterol or on-demand salbutamol (EFORA study)
Source: Eur Respir J 2002; 20: Suppl. 38, 107s
Year: 2002

A study to evaluate the therapeutic equivalence of a new multidose budesonide dry powder inhaler with a conventional budesonide dry powder inhaler
Source: Eur Respir J 2001; 18: Suppl. 33, 156s
Year: 2001

Efficacy and safety of salbutamol delivered via a novel multidose dry powder inhaler in comparison with two conventional dry powder inhalers and a pMDI in asthmatic subjects
Source: Eur Respir J 2001; 18: Suppl. 33, 50s
Year: 2001

Pharmacodynamic (PD), pharmacokinetic (PK) and safety profile of formoterol delivered via two different dry powder inhalers (DPIs)
Source: Eur Respir J 2006; 28: Suppl. 50, 614s
Year: 2006

Formoterol: a new pMDI CFC free formulation. cumulative dose safety versus a dry powder
Source: Eur Respir J 2003; 22: Suppl. 45, 473s
Year: 2003

Formoterol provides comparable bronchodilatation when delivered via dry powder (DPI) and metered dose inhalers (MDI) in adult asthma patients
Source: Eur Respir J 2005; 26: Suppl. 49, 339s
Year: 2005

Pharmacokinetics and pharmacodynamics of beclomethasone dipropionate and formoterol combination after inhalation using a new dry powder inhaler
Source: Eur Respir J 2007; 30: Suppl. 51, 350s
Year: 2007

Formoterol: a new pMDI CFC free formulation. Efficacy of the 12µg dosage versus a dry powder inhaler in moderate to severe asthmatic patients
Source: Eur Respir J 2003; 22: Suppl. 45, 284s
Year: 2003

Pharmacokinetics (PK) of a single dose AZD7594 administered intravenously (IV), orally, and inhaled via two dry powder inhalers (DPI) and a pressurized metered-dose inhaler (pMDI)
Source: International Congress 2017 – Pulmonary drug and devices delivery
Year: 2017

Lung bioavailability of beclometasone dipropionate and formoterol fumarate fixed dose combination administered using a pMDI or a novel DPI: NEXThaler®
Source: Annual Congress 2012 - The best of pharmacology treatments of airway diseases: new devices and drugs
Year: 2012


Lung deposition of formoterol in COPD patients: comparison of formoterol HFA pMDI, and formoterol dry powder inhaler
Source: Eur Respir J 2007; 30: Suppl. 51, 100s
Year: 2007

Efficacy, safety and cost of budesonide/formoterol in a single inhaler compared with budesonide plus formoterol as separate inhalers
Source: Eur Respir J 2002; 20: Suppl. 38, 43s
Year: 2002